Skip to main content
Premium Trial:

Request an Annual Quote

Cell Signaling Technology to Conduct Pilot Study for AstraZeneca to Find Biomarkers of Target Inhibition

NEW YORK, June 8 (GenomeWeb News) - Cell Signaling Technology will perform a pilot study for AstraZeneca to find biomarkers of target inhibition using its phospho-proteomics technology, the company said yesterday.

 

Cell Signaling, based in Beverly, Mass., will study compounds provided by AstraZeneca to find cellular protein tyrosine kinase phosphorylation profiles that indicate target inhibition.

 

The company will employ its Global Phospho-Signature technology, which combines immunoaffinity purification and mass spectrometry.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.